Aneesh K. Mehta
A5061697125- Viral Infections and Outbreaks Research
- Cytomegalovirus and herpesvirus research
- Disaster Response and Management
- Viral Infections and Vectors
- Immune Cell Function and Interaction
- SARS-CoV-2 and COVID-19 Research
- Renal Transplantation Outcomes and Treatments
- COVID-19 Clinical Research Studies
- T-cell and B-cell Immunology
- Herpesvirus Infections and Treatments
- Influenza Virus Research Studies
- Long-Term Effects of COVID-19
- Clostridium difficile and Clostridium perfringens research
- Pneumocystis jirovecii pneumonia detection and treatment
- Fungal Infections and Studies
- Hepatitis B Virus Studies
- Mycobacterium research and diagnosis
- COVID-19 epidemiological studies
- Immunotherapy and Immune Responses
- HIV/AIDS Research and Interventions
- Viral gastroenteritis research and epidemiology
- Diabetes and associated disorders
- Antifungal resistance and susceptibility
- Zoonotic diseases and public health
- Respiratory viral infections research
Emory University
2016-2025
Emory and Henry College
2014-2025
HOPE Clinic
2012-2025
Miami Transplant Institute
2024-2025
New York University
2021-2024
Mayo Clinic in Florida
2024
Emory University Hospital
2016-2024
Emory Healthcare
2012-2023
National Center for Emerging and Zoonotic Infectious Diseases
2022
Computer Emergency Response Team
2022
BackgroundAlthough several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), no antiviral yet shown to be efficacious.MethodsWe conducted a double-blind, randomized, placebo-controlled trial intravenous remdesivir in adults who were hospitalized with Covid-19 and had evidence lower respiratory tract infection. Patients randomly assigned receive either (200 mg loading dose on day 1, followed by 100 daily up 9 additional days) or placebo 10 days....
BackgroundSevere coronavirus disease 2019 (Covid-19) is associated with dysregulated inflammation. The effects of combination treatment baricitinib, a Janus kinase inhibitor, plus remdesivir are not known.MethodsWe conducted double-blind, randomized, placebo-controlled trial evaluating baricitinib in hospitalized adults Covid-19. All the patients received (≤10 days) and either (≤14 or placebo (control). primary outcome was time to recovery. key secondary clinical status at day 15.ResultsA...
The 2009 pandemic H1N1 influenza demonstrated the global health threat of reassortant strains. Herein, we report a detailed analysis plasmablast and monoclonal antibody responses induced by infection in humans. Unlike antibodies elicited annual vaccinations, most neutralizing were broadly cross-reactive against epitopes hemagglutinin (HA) stalk head domain multiple from cells that had undergone extensive affinity maturation. Based on these observations, postulate plasmablasts producing...
SARS-CoV-2, the virus responsible for COVID-19, is causing a devastating worldwide pandemic, and there pressing need to understand development, specificity, neutralizing potency of humoral immune responses during acute infection. We report cross-sectional study antibody receptor-binding domain (RBD) spike protein neutralization activity in cohort 44 hospitalized COVID-19 patients. RBD-specific IgG are detectable all patients 6 days after PCR confirmation. Isotype switching occurs rapidly,...
Among the survivors of Ebola virus disease (EVD), complications that include uveitis can develop during convalescence, although incidence and pathogenesis EVD-associated are unknown. We describe a patient who recovered from EVD was subsequently found to have severe unilateral convalescence. Viable Zaire ebolavirus (EBOV) detected in aqueous humor 14 weeks after onset 9 clearance viremia.
Ending the COVID-19 pandemic will require long-lived immunity to SARS-CoV-2. Here, we evaluate 254 patients longitudinally up 8 months and find durable broad-based immune responses. SARS-CoV-2 spike binding neutralizing antibodies exhibit a bi-phasic decay with an extended half-life of >200 days suggesting generation longer-lived plasma cells. infection also boosts antibody titers SARS-CoV-1 common betacoronaviruses. In addition, spike-specific IgG+ memory B cells persist, which bodes well...
We have previously shown that broadly neutralizing antibodies reactive to the conserved stem region of influenza virus hemagglutinin (HA) were generated in people infected with 2009 pandemic H1N1 strain. Such are rarely seen humans following infection or vaccination seasonal strains. However, important question remained whether inactivated vaccine, like infection, could also induce these antibodies. To address this question, we analyzed B-cell responses 24 healthy adults immunized vaccine...
Available data on the characteristics of patients with Ebola virus disease (EVD) and clinical management EVD in settings outside West Africa, as well complications observed those patients, are limited.We reviewed available clinical, laboratory, virologic from all laboratory-confirmed infection who received care U.S. European hospitals August 2014 through December 2015.A total 27 (median age, 36 years [range, 25 to 75]) care; 19 (70%) were male, 9 26 (35%) had coexisting conditions, 22 (81%)...
West Africa is currently experiencing the largest outbreak of Ebola virus disease (EVD) in history. Two patients with EVD were transferred from Liberia to our hospital United States for ongoing care. Malaria had also been diagnosed one patient, who was treated it early course EVD. The two substantial intravascular volume depletion and marked electrolyte abnormalities. We undertook aggressive supportive measures hydration (typically, 3 5 liters intravenous fluids per day care) correction. As...
Systems approaches have been used to describe molecular signatures driving immunity influenza vaccination in humans. Whether such are similar across multiple seasons and diverse populations is unknown. We applied systems study immune responses young, elderly, diabetic subjects vaccinated with the seasonal vaccine five consecutive seasons. Signatures of innate plasmablasts correlated predicted antibody titers at 1 month after >80% accuracy but were not associated longevity response. Baseline...
Significance In 2014, Ebola virus became a household term. The ongoing outbreak in West Africa is the largest ever recorded, with over 20,000 cases and 8,000 deaths to date. Very little known about human cellular immune response infection, this lack of knowledge has hindered development effective therapies vaccines. study, we characterize infection four patients. We define kinetics T- B-cell activation, determine which viral proteins are targets virus-specific T-cell humans.
Significance Vaccination is the most effective means of attaining protection against influenza viruses. However, constantly evolving nature viruses enables them to escape preexisting immune surveillance, and thus thwarts public health efforts control annual epidemics occasional pandemics. One solution elicit antibodies directed highly conserved epitopes, such as those within stem region HA, principal target virus-neutralizing antibody responses. This study shows that vaccines induce...
Background. The current West Africa Ebola virus disease (EVD) outbreak has resulted in multiple individuals being medically evacuated to other countries for clinical management.
Ebola virus (EBOV) remains a public health threat. We performed longitudinal study of B cell responses to EBOV in four survivors the 2014 West African outbreak. Infection induced lasting EBOV-specific immunoglobulin G (IgG) antibodies, but their subclass composition changed over time, with IgG1 persisting, IgG3 rapidly declining, and IgG4 appearing late. Striking changes occurred repertoire, massive recruitment naive cells that subsequently underwent hypermutation. characterized large panel...
¶ A list of severe manifestations monkeypox can be found at https://emergency
Multidrug-resistant organism (MDRO) colonization is a fundamental challenge in antimicrobial resistance. Limited studies have shown that fecal microbiota transplantation (FMT) can reduce MDRO colonization, but its mechanisms are poorly understood. We conducted randomized, controlled trial of FMT for decolonization renal transplant recipients called PREMIX (NCT02922816). Eleven participants were enrolled and randomized 1:1 to or an observation period followed by delayed if stool cultures...
Two patients with Lassa fever are described who the first human cases treated a combination of ribavirin and favipiravir. Both survived but developed transaminitis had prolonged detectable virus RNA in blood semen, suggesting that possibility sexual transmission should be considered.